Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024

Forte Biosciences, Inc.

Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.
Strategic alternatives committee formed including Camac nominees; rights plan expires July 12, 2024, not renewed, no new plan for 3 years.
Camac enters standstill/voting agreement through 2028; company pays $364k for Camac's 2023 proxy contest out-of-pocket expenses.
Settlement resolves claims that July 2023 private placement (~$25M) was intended to entrench board and block Camac director nominees.
The standstill prohibits Camac from acquiring additional shares, launching proxy contests, or seeking board representation until 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.